-
Cerevel Therapeutics Holdings, Inc. was an
American biotechnology and
pharmaceuticals company based in Cambridge, M****achusetts,
focused on the development...
-
treatment of both
schizophrenia and Alzheimer's
disease psychosis developed by
Cerevel Therapeutics. On
November 11, 2024,
AbbVie announced that
phase 2 clinical...
-
December 2023,
AbbVie announced that it will
acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion, in an
attempt to
expand its drug pipeline...
-
biotechnology executive. He has
served as
chairman of the
board of
directors of
Cerevel Therapeutics, a
company focused on
neurological disease treatments, since...
- κ-opioid receptor. It was
originated by
Pfizer and is
under development by
Cerevel Therapeutics (a
subsidiary of AbbVie). As of
September 2022, icalcaprant...
- 7
billion Cerevel sale". Reuters.
Retrieved January 2, 2024. Bunker, Ted (December 7, 2023). "Bain
Capital Banks M****ive
Return on
Cerevel Deal". The...
-
development for the
treatment of Parkinson's disease. It is
under development by
Cerevel Therapeutics,
which acquired tavapadon from
Pfizer in 2018. It is taken...
- well-tolerated.
Darigabat was
originated by
Pfizer and is
under development by
Cerevel Therapeutics and Pfizer. As of
January 2023, it is in
phase 2 clinical...
- effects. The drug was
originated by
Pfizer and is
under development by
Cerevel Therapeutics. As of
April 2022,
razpipadon is in
phase 2
clinical trials...
-
Publicly Listed Leader in
Neuroscience Drug
Development -
Cerevel Therapeutics". www.
cerevel.com. July 30, 2020.
Retrieved March 11, 2024. "Perceptive...
